Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 3/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
| ▸ | CCKBR | P32239 | 6/20 | 0.34 |
| ▸ | CCKAR | P32238 | 5/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4897316 | 0.88 | PYGL (0.39) | RIPK1SCN9ACCKBRCCKARDPP4 | |
| SCHEMBL4897302 | 0.87 | RIPK1 (0.34) | RIPK1SCN9ASCN10ADPP4DPP8 | |
| SCHEMBL4894329 | 0.85 | SCN9A (0.35) | RIPK1SCN9ACCKBRCCKARDPP4 | |
| SCHEMBL4895620 | 0.83 | SCN9A (0.44) | RIPK1SCN9ACCKBRCCKAR | |
| SCHEMBL4897701 | 0.83 | SCN9A (0.39) | RIPK1SCN9ACCKBRDPP4 | |
| SCHEMBL4891499 | 0.82 | DPP4 (0.47) | RIPK1DPP4DPP8 | |
| SCHEMBL8273798 | 0.81 | SCN9A (0.48) | SCN9ACCKBRCCKARSCN10A | |
| SCHEMBL4893208 | 0.81 | CCKBR (0.36) | SCN9ACCKBRCCKARDPP4 | |
| SCHEMBL4896133 | 0.80 | SCN9A (0.39) | RIPK1SCN9A | |
| SCHEMBL4890017 | 0.79 | SCN9A (0.38) | RIPK1SCN9ACCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | RIPK1 3999/4885SCN9A 718/4885CCKBR 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.